UPDATE 1-U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer
May 15, 2020 at 09:14 AM EDT
The U.S. Food and Drug Administration declined to approve Blueprint Medicines Corp's therapy for previously treated patients with a type of cancer that affects the stomach and small intestine, the drugmaker said on Friday.
